British healthcare company GlaxoSmithKline's (GSK) (LON:GSK) COVID-19 vaccine candidate, developed with SK Bioscience Co Ltd (KRX:302440), a South Korean vaccine and biopharmaceutical company, has been submitted for regulatory approval in South Korea after positive Phase III clinical data, Reuters news agency reported on Friday.
GSK said that SK bioscience will also apply to the World Health Organisation (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.
According to GSK, an extended clinical trial is planned to test the vaccine's effectiveness against the Omicron COVID-19 variant.
Novavax's Nuvaxovid (NVX-CoV2373) receives Australian regulator's provisional registration
GSK reports positive trial data for RSV vaccine candidate
Agilent Launches New Oligonucleotide Analysis Software for Biopharma Research
Bavarian Nordic signs smallpox vaccine deal with Canadian government
Codagenix's IND application for CodaVax-RSV receives US FDA approval
PAI Life Sciences Doses First Healthy Volunteer in Schistosomiasis Vaccine Clinical Trial
Takeda and Moderna to transfer SpikevaxTM Japan marketing authorisation to Moderna